Contribute Try STAT+ Today

WASHINGTON — Politicians spent the better part of 2019 bickering over the best way to lower drug prices. But in the meantime, states, advocates — even the drug and insurance industries — were devising novel strategies for solving this perplexing challenge.

2020 will be the year many of those experimental ideas are tested. If they pan out, they’ll undoubtedly be models for other states or companies — and perhaps serve as inspiration for Washington, too. Below, STAT looks at three of the most interesting ideas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy